Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Genmab A/S
  6. Company
    GMAB   DK0010272202

GENMAB A/S

(GMAB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Genmab A/S
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.

Number of employees : 781 people.
Sales per Business
20192020Delta
DKK (in Million)%DKK (in Million)%
Antibody Therapeutics5,366100%10,111100% +88.43%
Sales per region
20192020Delta
DKK (in Million)%DKK (in Million)%
Denmark5,366100%10,111100% +88.43%
Managers
NameAgeSinceTitle
Jan G. J. van de Winkel592010President & Chief Executive Officer
Anthony Pagano422020Chief Financial Officer & Executive Vice President
Tahamtan Ahmadi472021Chief Medical Officer & Executive Vice President
Anthony Mancini492020Chief Operating Officer & Executive Vice President
Pernille Lyngvold Erenbjerg522020Deputy Chairman
Paolo Augusto Paoletti, Dr.692015Independent Director
Rolf K. Hoffmann622016Independent Director
Deirdre Connelly592020Chairman
Jonathan M. Peacock622020Independent Director
Marisol Peron--SVP-Global Investor Relations & Communications
Members of the board
NameAgeSinceTitle
Deirdre Connelly592020Chairman
Anders Gersel Pedersen, Dr.68-Non-Independent Director
Pernille Lyngvold Erenbjerg522020Deputy Chairman
Paolo Augusto Paoletti, Dr.692015Independent Director
Peter Storm Kristensen452016Non-Independent Director
Rolf K. Hoffmann622016Independent Director
Mijke Zachariasse, Dr.462019Non-Independent Director
Jonathan M. Peacock622020Independent Director
Rima Bawarsh Nassar, Dr.662019Non-Independent Director
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 65,620,740 62,377,209 95.1% 202,977 0.3% 95.1%
Shareholders
NameEquities%
Baillie Gifford & Co. 3,672,198 5.60%
Wellington Management Co. LLP 2,179,074 3.32%
Artisan Partners LP 1,962,713 2.99%
The Vanguard Group, Inc. 1,466,284 2.23%
Norges Bank Investment Management 1,326,957 2.02%
BlackRock Fund Advisors 1,082,598 1.65%
BlackRock Advisors LLC 875,334 1.33%
Edgepoint Investment Group, Inc. 865,782 1.32%
GQG Partners LLC 811,405 1.24%
Capital Research & Management Co. (World Investors) 682,131 1.04%
Holdings
NameEquities%Valuation
Genmab A/S (GMAB) 254,2060.39%102,928,576 USD
Company contact information
Genmab A/S
Kalvebod Brygge 43
Copenhagen, Capital Region 1560

Phone : +45.70.20.27.28
Fax : +45.70.20.27.29
Web : http://www.genmab.com
Sector Bio Therapeutic Drugs
1st jan.Capitalization (M$)
GENMAB A/S10.52%28 359
GILEAD SCIENCES, INC.14.33%83 541
WUXI APPTEC CO., LTD.24.70%63 775
REGENERON PHARMACEUTICALS11.35%55 705
BIONTECH SE160.57%51 304
VERTEX PHARMACEUTICALS-20.52%48 628
BEIGENE, LTD.24.54%29 784
ARGENX SE10.41%16 252
HUALAN BIOLOGICAL ENGINEERING INC.-14.44%10 217
NEUROCRINE BIOSCIENCES, INC.4.87%9 504
DENALI THERAPEUTICS INC.-11.97%8 936
ARROWHEAD PHARMACEUTICALS, INC.11.61%8 914
MIRATI THERAPEUTICS, INC.-24.17%8 568
REMEGEN CO., LTD.34.63%8 070
ACCELERON PHARMA INC.0.23%7 784
ASCENDIS PHARMA A/S-15.49%7 587
FATE THERAPEUTICS, INC.-11.77%7 544
EXELIXIS, INC.11.66%7 023
GW PHARMACEUTICALS PLC89.72%6 907
AKESO, INC.62.63%6 504
ULTRAGENYX PHARMACEUTICAL INC.-31.43%6 405